Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Do all leukoreduction filters perform the same? Not really…
In transfusion medicine, not all filters are equal. Behind what looks like a simple device lie technical choices that directly impact patient safety and blood product quality. So… how do you know which one is the right filter?
Here are the 4 key criteria:
Leukoreduction performance
• European standard: ≤ 1 million residual white blood cells
• AABB standard: ≤ 5 million
In practice, users often expect a filter to perform 5 to 10 times better than these limits, to ensure stability and safety.
Residual losses
An efficient filter retains leukocytes… but it may also trap red blood cells. Too much loss = a direct impact on hemoglobin levels, or on the required minimum recovery (≥ 85% according to AABB). The challenge is to find the right balance.
Filtration speed
Some centers want ultra-fast processing. Others prefer quality over speed. It all depends on the number of units to process daily and the available “masked time.”
Final component quality
Filters also influence hemolysis in red blood cells or platelet activation in PC. An invisible variable… but one that determines therapeutic value.
Conclusion – there is no such thing as a “perfect” filter. The right filter is the one that fits your process, your priorities, and your patients.
And you, which of these criteria weighs the most in your decisions?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring